🇺🇸 FDA
Company

ORAMED

ORAMED PHARMACEUTICALS INC.

ORMP pharma USA

Quick answer

ORAMED is a pharma company (ORMP) headquartered in NEW YORK, NY, USA with 14 tracked pipeline programs.

Pipeline (14)

project

ORMD-0801

Diabetes Mellitus, Type 2

Phase 3 · small_molecule · active

2 trials project

ORMD-0801

T2DM (Type 2 Diabetes Mellitus)

Phase 3 · small_molecule · terminated

1 trials project

ORMD-0801 (qd)

Type 2 Diabetes Mellitus

Phase 3 · small_molecule · completed

2 trials project

ORMD-0801 8 mg

Type 2 Diabetes Mellitus

Phase 3 · small_molecule · active

1 trials project

Cohort A: ORMD-0801

T2DM (Type 2 Diabetes Mellitus)

Phase 2 · small_molecule · completed

1 trials project

ORMD 0801

Brittle Type I Diabetes Mellitus

Phase 2 · small_molecule · completed

1 trials project

ORMD-0801

Diabetes Type 2

Phase 2 · small_molecule · completed

1 trials project

ORMD-0801 (Insulin) capsule 8 mg BD

Diabetes Mellitus, Type 2

Phase 2 · small_molecule · completed

1 trials project

ORMD-0801 Capsules

Diabetes Mellitus Type 1

Phase 2 · mab · completed

1 trials project

ORMD-0801 Dose # 1

Diabetes Mellitus Type 2

Phase 2 · small_molecule · completed

1 trials project

ORMD-0801 QD

Nonalcoholic Steatohepatitis (NASH)

Phase 2 · small_molecule · completed

1 trials project

ORMD-0801 Treatment A

Type 1 Diabetes

Phase 2 · small_molecule · completed

1 trials project

ORMD-0801 capsules- 2x8mg

Type 1 Diabetes

Phase 2 · small_molecule · completed

1 trials project

Oral Insulin

Non-Alcoholic Steatohepatitis (NASH)

Phase 2 · mab · completed

1 trials

Patents (8)

patent

US 11660327

Methods and compositions for oral administration of proteins

Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11395848

Methods and compositions for treating diabetes

Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10967051

Methods and compositions for treating NAFLD, hepatic steatosis, and sequelae the

Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10933022

Protease inhibitor-containing compositions, compositions comprising same, and me

Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10881714

Methods and compositions for oral administration of proteins

Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10398762

Methods and compositions for treating diabetes

Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10350162

Methods and compositions for oral administration of exenatide

Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10342764

Protease inhibitor-containing compositions, compositions comprising same, and me

Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)